Stabilized pacap peptide

Stabilizing PACAP peptides by substituting aspartic acid residues with tetrazole or oxadiazolone-substituted variants enhances their stability and efficacy in aqueous solutions, enabling effective therapeutic uses for neurological disorders and dry eye treatment.

JP2024166370APending Publication Date: 2024-11-28SENJU PHARMA CO LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2024161236
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-05-14
Filing Date
2024-09-18
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

PACAP peptides are unstable in aqueous solutions due to lack of protease resistance, leading to short half-lives and limited effectiveness in therapeutic applications.

Method used

Substituting aspartic acid residues at positions 3 and 8 of PACAP with tetrazole-substituted aspartic acid, tetrazole-substituted glutamic acid, tetrazole-substituted homoglutamic acid, sulfoxy-substituted aspartic acid, or oxadiazolone-substituted aspartic acid to enhance stability in aqueous solutions while maintaining binding to PAC1R and VPAC1R receptors.

Benefits of technology

The modified peptides exhibit significantly improved stability in aqueous solutions, retaining physiological activities such as neuroprotection, neurite formation promotion, and lacrimal secretion, making them suitable for therapeutic applications like dry eye treatment and neurological disorder prevention.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024166370000001
    Figure 2024166370000001
  • Figure 2024166370000002
    Figure 2024166370000002
  • Figure 2024166370000003
    Figure 2024166370000003
Patent Text Reader

Abstract

To provide a PACAP peptide having improved stability.SOLUTION: The present invention is based on the finding that the stability of PACAP is significantly improved by substituting aspartic acid at positions 3 and 8 in the sequence of PACAP with at least one amino acid selected from the group consisting of tetrazole-substituted aspartic acid (Tz), tetrazole-substituted glutamic acid (egTz), tetrazole-substituted homoglutamic acid (nvTz), sulfoxy-substituted aspartic acid (cya), and oxadiazolone-substituted aspartic acid (5Oxa).SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a stabilized peptide having the physiological activity of PACAP, a neuroprotective agent, an agent for improving vascular endothelial function, an agent for promoting corneal neurite formation, an agent for promoting tear secretion, an agent for treating dry eye, an agent for treating corneal epithelium or corneal endothelial disorder, an agent for treating neurotrophic keratitis, an anti-inflammatory agent, or a pharmaceutical composition containing the peptide. [Background technology]

[0002] Neurons are cells that make up the nervous system, which is broadly divided into the central nervous system and the peripheral nervous system. Neurons are easily damaged by external factors such as cerebrovascular disorders such as stroke and cerebral infarction, and by internal factors such as accumulation of abnormal proteins, oxidative stress, and inflammation. However, because of their low regenerative ability, once damage occurs, it significantly reduces the patient's quality of life. Neurodegenerative diseases involving neurodegeneration and loss of the central nervous system include neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and multiple sclerosis, as well as degenerative diseases of the optic nerve such as glaucoma and optic neuropathy, and sensory neurodegenerative diseases such as nerve hearing loss.

[0003] With the development of neuroscience, various neuroprotective factors have been discovered, and their development as preventive or therapeutic drugs for neurological disorders is expected. Drugs that reduce free radicals and excitatory amino acids that cause neurodegeneration, and drugs that can protect and / or repair nerve cells (e.g., immunophilin ligands such as neurotrophic factors and immunosuppressants) have been found to have neuroprotective effects. On the other hand, endogenous proteins such as pituitary adenylate cyclase-activating polypeptide (PACAP), CD44, and human brain carboxypeptidase B (HBCPB) have been found to have neuroprotective effects (Patent Documents 1 and 2).

[0004] Pituitary adenylate cyclase-activating polypeptide (PACAP) is a neuropeptide discovered in sheep hypothalamic extracts. PACAP may have the activity of stimulating cAMP formation in anterior pituitary cells. PACAP exists as PACAP38, which consists of 38 amino acid residues, and PACAP27, which consists of 27 amino acid residues, and both have equivalent effects (Non-Patent Documents 1 and 2). PACAP belongs to the vasoactive intestinal polypeptide (VIP) / secretin / glucagon superfamily, and the sequence of human PACAP27 has 68% identity with vasoactive intestinal polypeptide (VIP). PACAP and VIP bind to PAC1 receptor (PAC1R), VPAC1 receptor (VPAC1R), and VPAC2 receptor (VPAC2R), but differ in terms of their affinity for these receptors. PAC1R binds to PACAP with high selectivity. The affinity of PAC1R for PACAP is more than 1000 times higher than the affinity of PAC1R for VIP. On the other hand, both VPAC1R and VPAC2R have similar affinities for PACAP and VIP. PACAP has various physiological actions, and is known to have physiological actions as a neuroprotective substance, an immunosuppressant, a vasodilator, an exocrine gland secretion promoter (Patent Document 3), and a neurite outgrowth promoter (Patent Document 4).

[0005] The diverse physiological activities of PACAP have been utilized in the development of pharmaceuticals, but peptides such as PACAP are often unstable in aqueous solutions and have short half-lives due to lack of protease resistance. [Prior art documents] [Patent documents]

[0006] [Patent Document 1] Special Publication No. 2014-510101 [Patent Document 2] JP 2012-232952 A [Patent Document 3] JP 2009-269818 A [Patent Document 4] WO2005 / 102375 Brochure [Non-patent literature]

[0007] [Non-Patent Document 1] S. Bourgault (2009) Current Medicinal Chemistry 16, 4462-4480 [Non-Patent Document 2] Louise Dickson (2009) Pharmacology & Therapeutics, 12, 294-316 Summary of the Invention [Problem to be solved by the invention]

[0008] The present invention aims to provide a stabilized peptide of PACAP that is highly stable in an aqueous solution, a neuroprotective agent, a neurite outgrowth promoter, a lacrimal gland secretion promoter, a pharmaceutical composition for treating or preventing dry eye, a pharmaceutical composition for treating or preventing corneal epithelial or corneal endothelial disorders, a pharmaceutical composition for treating or preventing nerve disorders, or a composition for treating or preventing neurotrophic keratitis, each of which contains said peptide. [Means for solving the problem]

[0009] As a result of intensive research conducted by the present inventors to increase the stability of PACAP in aqueous solution, they discovered that stability in aqueous solution can be significantly increased by independently replacing the aspartic acids at positions 3 and 8 in the PACAP peptide with residues selected from the group consisting of tetrazole-substituted aspartic acid (Tz), tetrazole-substituted glutamic acid (egTz), tetrazole-substituted homoglutamic acid (nvTz), sulfoxy-substituted aspartic acid (cya), and oxadiazolone-substituted aspartic acid (5Oxa), thereby completing the present invention.

[0010] Thus, the present invention relates to: [1] H-X1-DG-X2-F-X3-D-X4-Y-X5-RYRK-X6-X7-AVKKYLAAVL (Sequence number 3) {In the formula, X1 is a neutral amino acid, X2 is a neutral amino acid, X3 is a neutral amino acid, X4 is alanine, serine, Ai or Cn; X5 is alanine, serine, Ai or Cn; X6 is glutamine or alanine X7 is a non-polar amino acid} a peptide having a sequence in which aspartic acid at positions 3 and 8 of the sequence represented by the formula (I) is independently substituted with a residue selected from the group consisting of tetrazole-substituted aspartic acid (Tz), tetrazole-substituted glutamic acid (egTz), tetrazole-substituted homoglutamic acid (nvTz), sulfoxy-substituted aspartic acid (cya), and oxadiazolone-substituted aspartic acid (5Oxa), or a modified sequence thereof, wherein the peptide has binding ability to PAC1R and VPAC1R, and the modified sequence is a sequence in which one or more amino acids have been deleted or added in the sequence of SEQ ID NO: 3. [2] The peptide according to item 1, wherein X1 is serine or alanine. [3] The peptide according to item 1 or 2, wherein X2 is isoleucine or alanine. [4] The peptide according to any one of items 1 to 3, wherein X3 is alanine or threonine. [5] The peptide according to any one of items 1 to 4, wherein X7 is methionine, leucine, norleucine, or alanine. [6] The peptide according to any one of items 1 to 5, wherein when the amino acids at positions 3 and 8 are tetrazole-substituted aspartic acid (Tz), tetrazole-substituted glutamic acid (egTz), or tetrazole-substituted homoglutamic acid (nvTz), respectively, these amino acids are in the L-form, D-form, or racemic form. [7] The peptide according to any one of items 1 to 6, wherein the N-terminus of the peptide is modified with a protecting group. [8] The peptide according to item 7, wherein the protecting group is an acyl group. [9] The peptide according to any one of items 1 to 8, wherein the C-terminus of the peptide is modified with a protecting group.

[10] The peptide according to item 9, wherein the protecting group is an amide group or an ester group.

[11] The peptide according to any one of items 1 to 10, wherein the modified sequence is a sequence in which 1 to 3 amino acids are deleted from the sequence at the C-terminus.

[12] The peptide according to any one of items 1 to 10, wherein the modified sequence is a sequence in which 1 to 3 amino acids have been added to the N-terminus of the sequence.

[13] The modified sequence is as follows: GKRYKQRVKNK (SEQ ID NO:43); GKRYKQRVKN (SEQ ID NO:44); GKRYKQRVK (SEQ ID NO:45); GKRYKQRV (SEQ ID NO:46); GKRYKQR (SEQ ID NO:47); GKRYKQ (SEQ ID NO:48); GKRYK (SEQ ID NO:49); GKRY (SEQ ID NO:50) GKR; GRR; GK; and GR G; 13. The peptide according to any one of items 1 to 10 or 12, wherein the peptide is a sequence having one sequence selected from the group consisting of:

[14] A neuroprotective agent comprising the peptide according to any one of items 1 to 13.

[15] A lacrimal secretion promoter comprising the peptide according to any one of items 1 to 13.

[16] An anti-inflammatory agent comprising the peptide according to any one of items 1 to 13.

[17] A vascular endothelial function improving agent comprising the peptide according to any one of items 1 to 13.

[18] A therapeutic agent for corneal epithelium or corneal endothelium disorder, comprising the peptide according to any one of items 1 to 13.

[19] A therapeutic agent for dry eye, comprising the peptide according to any one of items 1 to 13.

[20] A pharmaceutical composition comprising the peptide according to any one of items 1 to 13.

[21] A method for neuroprotection in a subject in need of neuroprotection, comprising administering to the subject an effective amount of the peptide described in any one of items 1 to 13.

[22] A method for promoting tear secretion in a subject in need of tear secretion, the method comprising administering to the subject a peptide described in any one of items 1 to 13.

[23] A method for improving vascular endothelial function in a subject in need of such improvement, comprising administering a peptide described in any one of items 1 to 13.

[24] A method for suppressing inflammation in a subject suffering from inflammation, the method comprising administering a peptide described in any one of items 1 to 13.

[25] A method for improving corneal epithelial or corneal endothelial disorder in a subject suffering from corneal epithelial or corneal endothelial disorder, the method comprising administering a peptide described in any one of items 1 to 13.

[26] A method for treating or preventing dry eye in a subject suffering from dry eye, the method comprising administering a peptide described in any one of items 1 to 13.

[27] The peptide according to any one of items 1 to 13 for use as a pharmaceutical.

[28] The peptide according to any one of items 1 to 13 for use in treating a neurological disorder.

[29] The peptide according to any one of items 1 to 13 for use in the treatment or prevention of neurological disorders via neuroprotection.

[30] The peptide according to any one of items 1 to 13 for use in the treatment or prevention of dry eye and diseases associated with dry eye.

[31] The peptide according to any one of items 1 to 13 for use in treating or preventing a corneal epithelium or corneal endothelial disorder.

[32] The peptide according to any one of items 1 to 13 for use in treating or preventing an inflammatory disease.

[33] The peptide according to any one of items 1 to 13 for use in treating or preventing vascular endothelial disorder.

[34] Use of the peptide according to any one of items 1 to 13 for the manufacture of a medicine selected from the group consisting of neuroprotective agents, lacrimation promoters, anti-inflammatory agents, agents for improving vascular endothelial function, agents for treating corneal epithelial or corneal endothelial disorders, and agents for treating dry eye. Effect of the Invention

[0011] According to the present invention, PACAP, which was unstable in an aqueous solution, can be significantly stabilized. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0012] The present invention relates to a peptide having a sequence in which the aspartic acid residues at positions 3 and 8 of PACAP are independently replaced with a residue selected from the group consisting of tetrazole-substituted aspartic acid (Tz), tetrazole-substituted glutamic acid (egTz), tetrazole-substituted homoglutamic acid (nvTz), sulfoxy-substituted aspartic acid (cya), and oxadiazolone-substituted aspartic acid (5Oxa), or a sequence in which a part of the sequence is modified, and such a peptide has a binding affinity to PAC1R, VPAC1R, and / or VPAC2R comparable to that of PACAP. Comparable binding may mean that the EC50 value of the peptide to each receptor is within 100 times that of PACAP. PACAP may be either PACAP38 consisting of 38 residues or PACAP27 consisting of 27 residues. PACAP38 and PACAP27 have the following sequences: PACAP38: HSDGIFTDSYSRYRKQMAVKKYLAAVLGKRYKQRVKNK (SEQ ID NO: 1) PACAP27: HSDGIFTDSYSRYRKQMAVKKYLAAVL (SEQ ID NO: 2)

[0013] In the present invention, tetrazole-substituted aspartic acid (Tz), tetrazole-substituted glutamic acid (egTz), and tetrazole-substituted homoglutamic acid (nvTz) refer to unnatural amino acid residues having a structure in which the carboxy group in the side chain of aspartic acid, glutamic acid, and homoglutamic acid is substituted with tetrazole, which is an isostere of the carboxy group, respectively. Specifically, they are represented by the following formula: [ka]

[0014] In the present invention, sulfoxy-substituted aspartic acid (cya) and oxadiazolone-substituted aspartic acid (5Oxa) refer to residues having a structure in which the carboxy group in the side chain of aspartic acid is replaced with a sulfoxy group, which is an isostere of the carboxy group, or 1,2,4-oxadiazol-5-one (oxadiazolone), respectively. Specifically, they are represented by the following formula: [ka]

[0015] The non-natural amino acid residues in which the aspartic acids at positions 3 and 8 are substituted may be in the L-form, D-form, or racemic form, so long as they have the same level of physiological activity as PACAP. In particular, a peptide substituted with an L-form tetrazole-substituted aspartic acid and a peptide substituted with a D-form tetrazole-substituted aspartic acid have the same level of binding affinity to PAC1R, VPAC1R, and / or VPAC2R. Although not intending to be limited by theory, the inclusion of D-form amino acids may make them less susceptible to enzyme decomposition and increase stability. Non-natural amino acids other than proteinogenic amino acids can also be introduced into peptides by introducing a protecting group by a method such as the Fmoc method, in the same manner as proteinogenic amino acids.

[0016] In the present invention, a partially modified sequence refers to a sequence in which one or more amino acids have been substituted, deleted, or added to the original sequence, more preferably, a partially modified sequence refers to a sequence in which one or several amino acids have been substituted, deleted, or added to the original sequence.

[0017] The amino acid substitution may occur at any position as long as it does not change the binding ability of the peptide consisting of a partially modified sequence to PAC1R, VPAC1R, and / or VPAC2R. In a peptide consisting of a partially modified sequence, amino acid substitutions may occur at positions 2, 5, 7, 9, 11, 16, and 17 of PACAP27 in order to maintain binding ability. In a particularly preferred embodiment, the peptide has the following sequence: H-X1-DG-X2-F-X3-D-X4-Y-X5-RYRK-X6-X7-AVKKYLAAVL (SEQ ID NO: 3) In this formula, the amino acids at the positions indicated by X1 to X7 may be substituted.

[0018] Thus, one aspect of the present invention is a compound having the formula: H-X1-DG-X2-F-X3-D-X4-Y-X5-RYRK-X6-X7-AVKKYLAAVL (SEQ ID NO: 3) {In the formula, X1 to X6 are neutral amino acids, X7 is a non-polar amino acid} The present invention relates to a peptide having a sequence represented by the formula: wherein the aspartic acids at positions 3 and 8 are each independently substituted with a residue selected from the group consisting of tetrazole-substituted aspartic acid (Tz), tetrazole-substituted glutamic acid (egTz), tetrazole-substituted homoglutamic acid (nvTz), sulfoxy-substituted aspartic acid (cya), and oxadiazolone-substituted aspartic acid (5Oxa), or a modified sequence thereof, and which has the ability to bind to PAC1R, VPAC1R, and / or VPAC2R.

[0019] Conservative substitutions may be made with amino acids having the same properties. By way of example, conservative substitutions refer to the substitution of amino acids within the following groups: (i) Nonpolar amino acids: Val, Leu, Ile, Met, Phe, Trp, Pro, Nle, Ala (ii) Neutral amino acids: Ala, Ser, Thr, Tyr, Cys, Asn, Gln, Gly (iii) Basic amino acids: Lys, Arg, His (iv) Acidic amino acids: Asp, Glu

[0020] Among the neutral amino acids, α-aminoisobutyric acid (Ai) in which a methyl group is substituted at the α-position of alanine, or β-cyanoalanine (Cn) in which a cyano group is substituted at the β-position of alanine, can be used instead of alanine. In particular, α-aminoisobutyric acid (Ai) and β-cyanoalanine (Cn) can be used as the 9-position and 11-position neutral amino acids. α-aminoisobutyric acid (Ai) and β-cyanoalanine (Cn) have the following structures: [ka]

[0021] In the sequence represented by SEQ ID NO:3 of the present invention, the amino acids represented by X1 to X7 are preferably as follows: The neutral amino acid at X1 is in particular alanine or serine. The neutral amino acid at X2 is in particular isoleucine or alanine. The neutral amino acid at X3 is in particular alanine or threonine. The neutral amino acid at X4 and X5 is in particular alanine, serine, alpha-aminoisobutyric acid, or beta-cyanoalanine. The neutral amino acid at X6 is in particular glutamine or alanine. The non-polar amino acid at X7 is in particular methionine, leucine, norleucine, or alanine.

[0022] In the present invention, a modified sequence refers to a sequence in which one or more amino acids have been substituted, deleted, or added to the original sequence. More preferably, a partially modified sequence refers to a sequence in which one or several amino acids have been substituted, deleted, or added to the original sequence.

[0023] The amino acid substitution may involve the substitution of one or more amino acids, but from the viewpoint of maintaining activity, any number of amino acids from 1 to 10, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, may be substituted. Of these, substitution of 1 to 4 amino acids is particularly preferred, substitution of 3 amino acids is more preferred, substitution of 2 amino acids is even more preferred, and substitution of 1 amino acid is particularly preferred.

[0024] The deletion of amino acids may occur at any position as long as the binding ability of the peptide consisting of a partially modified sequence to PAC1R, VPAC1R, and / or VPAC2R is not changed. The number of amino acids to be deleted is selected from any number between 1 and 10, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. From the viewpoint of not changing the binding ability, deletion of one or two amino acids, and further deletion of one amino acid, is particularly preferred. The deletion of amino acids may be from the N-terminus or C-terminus of the original sequence, or may be from the inside of the sequence. Since PACAP27 and PACAP38 have equivalent binding ability to PAC1R, VPAC1R, and / or VPAC2R, respectively, it is considered that the deletion of amino acids present on the C-terminus side of PACAP38 has little effect on the binding ability.

[0025] The addition of amino acids may occur at any position as long as the binding ability of the peptide consisting of a partially modified sequence to PAC1R, VPAC1R, and / or VPAC2R is not changed. The number of added amino acids is selected from any number between 1 and 10, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. The amino acids may be added to the N-terminus or C-terminus of the original sequence, or may be added internally to the sequence. Since PACAP27 and PACAP38 have equivalent binding ability to PAC1R, VPAC1R, and / or VPAC2R, respectively, it is considered that the binding ability is not significantly affected even if any amino acid is added to the C-terminus of PACAP27.

[0026] In the sequence of SEQ ID NO: 3, the aspartic acid residues at positions 3 and 8 are each independently replaced with a residue selected from the group consisting of tetrazole-substituted aspartic acid (Tz), tetrazole-substituted glutamic acid (egTz), tetrazole-substituted homoglutamic acid (nvTz), sulfoxy-substituted aspartic acid (cya), and oxadiazolone-substituted aspartic acid (5Oxa). The modified sequence is preferably a sequence in which one or more amino acids are deleted or added to the amino acid sequence represented by SEQ ID NO: 3. More preferably, one or two amino acids may be deleted from the amino acid sequence represented by SEQ ID NO: 3, and the following C-terminal additional sequence may be added to the amino acid sequence represented by SEQ ID NO: 3. In addition, one to three amino acids (e.g., methionine) may be added to the N-terminus of the amino acid sequence represented by SEQ ID NO: 3.

[0027] Without intending to be limited by theory, PACAP27 and PACAP38 each have equivalent binding affinity to PAC1R, VPAC1R, and / or VPAC2R, and therefore addition of amino acids to the C-terminus of PACAP27 does not affect binding affinity to PAC1R. Thus, a peptide of a modified sequence of the present invention can include a C-terminal additional sequence at the C-terminus of the amino acid sequence of SEQ ID NO: 3, similar to PACAP27. The C-terminal additional sequence refers to a sequence consisting of any amino acid of 1 to 11. It is preferable that the C-terminal additional sequence corresponds to the amino acids at positions 28 to 38 of PACAP38. Thus, examples of C-terminal sequences include the following sequences: GKRYKQRVKNK (SEQ ID NO:43); GKRYKQRVKN (SEQ ID NO:44); GKRYKQRVK (SEQ ID NO:45); GKRYKQRV (SEQ ID NO:46); GKRYKQR (SEQ ID NO:47); GKRYKQ (SEQ ID NO:48); GKRYK (SEQ ID NO:49); GKRY (SEQ ID NO:50) GKR; GRR; GK; and G R; G.

[0028] The peptide according to the present invention may use amino acids in the D-form or L-form, or may use racemic amino acids, so long as the binding ability to PAC1R, VPAC1R, and / or VPAC2R is not lost. Similarly, the peptide according to the present invention may be composed of unnatural amino acids such as 2-aminoisobutyric acid, and includes derivatives in which the amino group at the N-terminus, the carboxy group at the C-terminus, or the functional group at the amino acid side chain are optionally modified. Examples of modifications include addition of a protecting group to an amino group (e.g., acylation (formylation, acetylation, propionylation, butyrylation, isobutyrylation, etc.), mesylation, urea, carbamate, Boc, Fmoc), esterification of a carboxy group (ethylation, etc.), and the like. In addition to modifications that can normally occur in vivo, such as phosphorylation, amidation, methylation, esterification, acetylation, and the like, modifications that occur during synthesis or that facilitate purification, such as biotinylation, may also be included. Modifications such as PEGylation may be performed for the purpose of extending the half-life of the peptide in vivo. In particular, from the viewpoint of enhancing stability, the free amino group of the N-terminal amino acid may be protected by a protecting group (e.g., an acyl group). For example, the free amino group of the N-terminal amino acid may be acylated (e.g., acetylated, propionylated, butyrylated, isobutyrylated) or mesylated. Similarly, the free carboxyl group of the C-terminal amino acid may be protected by a protecting group (e.g., an amide group, an ester group). For example, the free carboxyl group of the C-terminal amino acid may be amidated or esterified. In the peptide of the present invention, the stability is further improved by acetylating or mesylating the N-terminus. The C-terminus may be any of a carboxyl group (-COOH), a carboxylate (-COO-), an amide (-CONH2), or an ester (-COOR). The peptide of the present invention may further be glycosylated (see, for example, WO2017 / 027848).

[0029] In a specific embodiment, the present invention relates to peptides having the sequences shown in Table 1 below, or modified sequences thereof: [Table 1]

[0030] In the table, Tz stands for tetrazole-substituted aspartic acid, egTz stands for tetrazole-substituted glutamic acid, nvTz stands for tetrazole-substituted homoglutamic acid, cya stands for sulfoxy-substituted aspartic acid, (5Oxa) stands for oxadiazolone-substituted aspartic acid, Ai stands for α-aminoisobutyric acid, and Cn stands for β-cyanoalanine. Tz(D) indicates that the tetrazole-substituted aspartic acid is the D-form.

[0031] The peptide of the present invention can be produced by any production method. For example, it can be produced by solid-phase synthesis or liquid-phase synthesis using the Boc method, Fmoc method, or the like. Alternatively, it can be produced by introducing a nucleic acid encoding the peptide of the present invention into a host cell by gene transfer and allowing the host cell to synthesize the peptide. In this case, purification after expression can be facilitated by designing the peptide so that a tag peptide such as a polyhistidine tag is added to the end of the peptide.

[0032] The peptide according to the present invention includes pharma- ceutically acceptable salts. Examples of pharma-ceutically acceptable salts include salts with inorganic acids (e.g., hydrochloride, hydrobromide, sulfate, phosphate, etc.), salts with organic acids (e.g., methanesulfonate, benzenesulfonate, p-toluenesulfonate, formate, acetate, trifluoroacetate, oxalate, citrate, malonate, fumarate, maleate, tartrate, succinate, malate, etc.), and salts with bases (e.g., ammonium salt, methylpyridinium salt, acetylpyridinium salt, etc.). The peptide according to the present invention also includes hydrates or solvates.

[0033] An Fmoc-N-protected amino acid in which the side chain carboxyl group of an amino acid (aspartic acid) is substituted with tetrazole, which is an isostere of the carboxyl group, can be produced by using Fmoc-N-protected asparagine as a starting material, according to the method shown in Reaction Scheme 1 or a method analogous thereto. [ka] {In the formula, Trt is a trityl group. Also, H or a Trt group is substituted at N1 or N2 on the tetrazole.

[0034] In the method of reaction formula 1, in step A, a compound represented by (I) (e.g., asparagine whose amino group is protected with Fmoc) is reacted with EDCI in the presence of a base to produce compound (II). In step A, 1 to 50 equivalents, preferably 10 to 25 equivalents, of the base are used relative to compound (I). Examples of the base used include pyridine, 4-dimethylaminopyridine, triethylamine, N,N-diisopropylethylamine, N-methylmorpholine, and the like, and preferably pyridine. 1 to 10 equivalents, preferably 1 to 2 equivalents, of EDCI are used. The solvent is not particularly limited as long as it does not affect the reaction, and examples thereof include N,N-dimethylformamide, N,N-dimethylacetamide, toluene, dichloromethane, tetrahydrofuran, acetonitrile, and the like, and preferably acetonitrile. The reaction temperature is usually −10 to 60° C., and preferably 0 to 30° C., and the reaction time is 0.5 to 12 hours, and preferably 1 to 5 hours.

[0035] In step B, compound (II) is reacted with trimethylsilyl azide and dibutyltin oxide in toluene to produce compound (III). Trimethylsilyl azide is used in an amount of 1 to 5 equivalents, preferably 2 to 4 equivalents, based on compound (II). Dibutyltin oxide is used in an amount of 0.3 to 1 equivalent, preferably 0.7 to 0.95 equivalents, based on compound (II). The solvent is not particularly limited as long as it does not affect the reaction, and examples of the solvent include benzene, toluene, xylene, etc., and preferably toluene. The reaction time is usually 0.5 to 24 hours, and preferably 0.5 to 2 hours. The reaction time is usually 80 to 150°C, and preferably 80 to 100°C. Examples of the heating method include an oil bath, microwave, etc., and preferably microwave.

[0036] Next, in step C, compound (IV) can be produced by reacting trityl chloride in the presence of a base. Examples of the base used in step C include pyridine, 4-dimethylaminopyridine, triethylamine, N,N-diisopropylethylamine, N-methylmorpholine, and the like, and preferably N-methylmorpholine. The amount of the base used is 1 to 3 equivalents, preferably 1 to 1.5 equivalents, relative to compound (IX). Trityl chloride is used in 1 to 3 equivalents, preferably 1.05 to 1.1 equivalents. The solvent is not particularly limited as long as it does not affect the reaction, and examples thereof include N,N-dimethylformamide, N,N-dimethylacetamide, toluene, dichloromethane, tetrahydrofuran, acetonitrile, and the like, and preferably tetrahydrofuran. The reaction temperature is usually -10 to 60°C, and preferably 0 to 30°C. The reaction time is 0.5 to 12 hours, and preferably 1 to 2 hours.

[0037] Fmoc-nvTz(Trt)-OH, in which tetrazole is bound to the α-position of an amino acid via an alkyl group having a carbon number of 3, can be produced by the method shown in Reaction Scheme 2 or a method analogous thereto. [ka]

[0038] In step D of the method of reaction formula 2, the compound represented by the general formula compound (V) is reacted with Boc2O in the presence of a base to produce compound (VI). The base is used in an amount of 1 to 10 equivalents, preferably 1 to 2 equivalents, relative to compound (V). Examples of the base used include triethylamine, N,N-diisopropylamine, N-methylmorpholine, sodium hydroxide, potassium carbonate, sodium hydrogen carbonate, and the like, and sodium hydroxide is preferred. Boc2O is used in an amount of 1 to 10 equivalents, preferably 1 to 2 equivalents, relative to compound (V). The solvent is not particularly limited as long as it does not affect the reaction, and examples include THF, DMF, 1,4-dioxane, and the like, and 1,4-dioxane is preferably used. The reaction temperature is usually 0 to 25°C, preferably 10 to 25°C. The reaction time is 1 to 24 hours, preferably 18 to 24 hours. In addition, N-methylpiperazine may be added to treat an excess amount of Boc2O, as long as it does not affect the reaction.

[0039] Next, in step E, compound (VI) is reacted with nickel sulfate hexahydrate, sodium peroxodisulfate, and sodium hydroxide to produce compound (VII). In step E, sodium peroxodisulfate is used in an amount of 1 to 4 equivalents, preferably 1 to 2 equivalents, based on compound (VI). Nickel sulfate hexahydrate is used in an amount of 0.01 to 0.1 equivalents, preferably 0.08 to 0.1 equivalents, based on compound (VI). The base used may be sodium hydroxide, which is used in an amount of 1 to 10 equivalents, preferably 6 to 8 equivalents, based on compound (VI). Water is used as the solvent. The reaction temperature is 10 to 40°C, preferably 10 to 25°C. The reaction time is usually 1 to 24 hours, preferably 12 to 24 hours.

[0040] Next, in step F, compound (VII) is reacted with TFA, the pH is adjusted to basic, and compound (VIII) is produced by reacting with Fmoc-OSu. Examples of the acid used in step F include hydrochloric acid, sulfuric acid, trifluoroacetic acid, etc., and preferably trifluoroacetic acid is used. The solvent is not particularly limited as long as it does not affect the reaction, and examples of the solvent include THF, dichloromethane, 1,4-dioxane, etc., and preferably dichloromethane is used. The reaction temperature is 0 to 25°C, and preferably 10 to 25°C. The reaction time is usually 0.5 to 5 hours, and preferably 0.5 to 2 hours. Examples of inorganic bases used to adjust the pH after the reaction and as a base include sodium hydroxide, potassium hydroxide, sodium hydrogen carbonate, sodium carbonate, potassium carbonate, etc., and preferably potassium carbonate is used. Fmoc-OSu is used in an amount of 1 to 3 equivalents, and preferably 1 to 1.5 equivalents, relative to compound (VII). The solvent is not particularly limited as long as it does not affect the reaction, and examples thereof include THF, N,N-dimethylformamide, dichloromethane, 1,4-dioxane, etc., and 1,4-dioxane is preferably used. The reaction temperature is 0 to 25° C., preferably 10 to 25° C. The reaction time is usually 1 to 36 hours, preferably 1 to 24 hours.

[0041] Next, in step G, compound (VIII) is reacted with trimethylsilyl azide and dibutyltin oxide in toluene to produce compound (IX). In step G, trimethylsilyl azide is used in an amount of 1 to 10 equivalents, preferably 2 to 4 equivalents, based on compound (II). Dibutyltin oxide is used in an amount of 0.3 to 1 equivalent, preferably 0.7 to 1.0 equivalent, based on compound (II). The solvent is not particularly limited as long as it does not affect the reaction, and examples of the solvent include benzene, toluene, xylene, etc., and preferably toluene. The reaction time is usually 0.5 to 48 hours, and preferably 0.5 to 2 hours. The reaction time is usually 80 to 150°C, and preferably 80 to 100°C. The heating method includes an oil bath, microwave, etc., and preferably microwave.

[0042] Next, in step H, compound (IX) is reacted with trityl chloride in the presence of a base to produce compound (X). In producing compound (X), examples of the base include pyridine, 4-dimethylaminopyridine, triethylamine, N,N-diisopropylethylamine, and N-methylmorpholine, and preferably N-methylmorpholine. The amount of base used is 1 to 3 equivalents, preferably 1 to 1.5 equivalents, relative to compound (IX). The amount of base used is 1 to 3 equivalents, preferably 1.05 to 1.1 equivalents, relative to trityl chloride compound (IX). The solvent is not particularly limited as long as it does not affect the reaction, and examples of the solvent include N,N-dimethylformamide, N,N-dimethylacetamide, toluene, dichloromethane, tetrahydrofuran, and acetonitrile, and preferably tetrahydrofuran. The reaction temperature is usually -10 to 60°C, preferably 20 to 30°C, and the reaction time is 0.5 to 12 hours, and preferably 1 to 2 hours.

[0043] Fmoc-(5Oxa)-OH in which the carboxy group of aspartic acid is substituted with 1,2,4-oxadiazol-5-one can be prepared by the method shown in Reaction Scheme 3 or a method analogous thereto. [ka]

[0044] In the method of reaction formula 3, in step I, the compound represented by the general formula compound (XI) is reacted with 2-bromo-2-methylpropane in the presence of benzyltriethylammonium chloride and a base to produce compound (XII). In step I, the base is used in an amount of 10 to 30 equivalents, preferably 10 to 25 equivalents, based on compound (XI). The base used can be potassium carbonate. Benzyltriethylammonium chloride is used in an amount of 1 to 3 equivalents, preferably 1 to 1.2 equivalents, based on compound (XI). 2-bromo-2-methylpropane is used in an amount of 10 to 50 equivalents, preferably 10 to 40 equivalents, based on compound (XI). N,N-dimethylacetamide is used as the solvent. The reaction temperature is usually 1 to 24 hours, preferably 18 to 24 hours. The reaction time is usually 25 to 70°C, preferably 25 to 55°C.

[0045] Next, in step J, compound (XII) is reacted with hydroxylamine hydrochloride in the presence of a base to produce compound (XIII). In step J, the base used may be triethylamine, N,N-diisopropylethylamine, etc., and preferably triethylamine. The base used in addition to compound (XII) is 1 to 3 equivalents, preferably 1 to 2 equivalents. Hydroxylamine hydrochloride is used in 1 to 2 equivalents, preferably 1 to 1.5 equivalents, relative to compound (XII). The solvent is not particularly limited as long as it does not affect the reaction, and examples of the solvent include methanol, ethanol, propanol, and isopropanol, and preferably ethanol. The reaction temperature is usually 80 to 100°C, and preferably 80 to 95°C. The reaction time is usually 1 to 6 hours, and preferably 1 to 4 hours.

[0046] Next, in step K, compound (XIII) is reacted with carbonyldiimidazole to produce compound (XIV). In step K, carbodiimidazole is used in an amount of 1 to 2 equivalents, preferably 1 to 1.2 equivalents, based on compound (XIII). The solvent is not particularly limited as long as it does not affect the reaction, and examples thereof include THF and 1,4-dioxane, and preferably THF. The reaction temperature is 40 to 60°C, and preferably 40 to 55°C. The reaction time is usually 1 to 6 hours, and preferably 1 to 3 hours. In the subsequent cyclization reaction, the solvent is not particularly limited as long as it does not affect the reaction, and examples thereof include toluene, xylene, benzene, and preferably toluene. The reaction temperature is usually 100 to 130°C, and preferably 100 to 120°C.

[0047] Next, in step L, compound (XIV) is reacted with TFA in the presence of a scavenger, the pH is adjusted to basic, and then the compound is reacted with Fmoc-OSu to produce (XV). In step L, examples of the acid used include hydrochloric acid, sulfuric acid, trifluoroacetic acid, and the like, and trifluoroacetic acid is preferably used. Examples of the scavenger used include triethylsilane and triisopropylsilane, and triethylsilane is preferably used. The solvent is not particularly limited as long as it does not affect the reaction, and examples of the solvent include THF, dichloromethane, 1,4-dioxane, and the like, and dichloromethane is preferably used. The reaction temperature is 0 to 25°C, and preferably 10 to 25°C. The reaction time is usually 0.5 to 5 hours, and preferably 0.5 to 3 hours. Examples of the inorganic base used for adjusting the pH after the reaction and as a base include sodium hydroxide, potassium hydroxide, sodium hydrogen carbonate, sodium carbonate, and potassium carbonate, and preferably sodium hydrogen carbonate. Fmoc-OSu is used in an amount of 1 to 3 equivalents, preferably 1 to 1.5 equivalents, relative to compound (VII). The solvent is not particularly limited as long as it does not affect the reaction, and examples thereof include THF, N,N-dimethylformamide, dichloromethane, 1,4-dioxane, etc., and 1,4-dioxane is preferably used at a reaction temperature of 0 to 25°C, preferably 10 to 25°C. The reaction time is usually 1 to 36 hours, preferably 1 to 24 hours.

[0048] The peptide according to the present invention can exert physiological activity similar to that of PACAP by binding to PAC1R, VPAC1R, and / or VPAC2R. That is, the peptide according to the present invention can exert physiological actions as, for example, a neuroprotective substance, a nerve regeneration factor, a wound healing promoting factor, an inflammation suppressing factor, or an exocrine gland secretion promoting factor. Therefore, another aspect of the present invention may relate to a neuroprotective agent, a nerve regeneration agent, a wound healing agent, an inflammation suppressing agent, a therapeutic agent for corneal epithelium or corneal endothelium disorder, a therapeutic agent for dry eye or an exocrine gland secretion promoting agent, or a therapeutic agent for neurotrophic keratitis, which comprises the peptide according to the present invention. In yet another aspect, the present invention also relates to a pharmaceutical composition comprising the peptide according to the present invention.

[0049] The neuroprotective agent according to the present invention refers to a drug having a neuroprotective effect. Therefore, the neuroprotective agent can protect nerves from disorders involving damage, degeneration and / or cell death of nerve cells, and can also be called an agent for suppressing neuronal death (apoptosis and / or necrosis), an agent for suppressing neuronal degeneration, an agent for reducing neuronal stress, an agent for improving neuronal toxicity resistance, an agent for improving neuronal viability, or an agent for suppressing abnormal protein accumulation.

[0050] In this specification, the neuroprotective effect refers to the effect of protecting nerve cells from damage, degeneration, and / or cell death, and preferably refers to the effect of protecting nerve cells from cell death. More specifically, the neuroprotective effect may include suppression of nerve cell death (apoptosis and / or necrosis), suppression of nerve cell degeneration, reduction of nerve cell stress, improvement of resistance to neuronal toxicity, improvement of nerve cell survival, suppression of abnormal protein accumulation, and the like. In addition to physical damage, nerve cells are damaged by exposure to neurotoxic substances and lack of oxygen and nutrients, and cell death is caused when the damage exceeds a certain level. In addition, nerve cells are degenerated by accumulating neurotoxic substances, and finally cell death is caused. Neurotoxic substances are broadly classified into exogenous toxic substances and endogenous toxic substances. Examples of exogenous toxic substances include chemical substances such as heavy metals, alcohol, and botulinum toxin. Examples of endogenous toxic substances include reactive oxygen species, neurotransmitters such as glutamic acid, and abnormal proteins. The neuroprotective effect can be easily measured by those skilled in the art. As an example, under various stress conditions such as hypoxia, exposure to neurotoxic substances, nutrient depletion, and ultraviolet irradiation, nerve cells are cultured in a medium containing the test substance (drug group) or a medium not containing the test substance (control group), the number of viable cells and the number of dead cells in the medium are measured, and the ratio of the number of viable cells to the total number of cells is calculated. If the ratio of the number of viable cells in the drug group is higher than the ratio of the number of viable cells in the control group, the test substance can be judged to have a neuroprotective effect. In a more preferred embodiment, the test substance can be compared with a positive control group to which a substance known to have a neuroprotective effect, such as IGF-1 or NGF, is added, and the test substance can be determined to have a protective effect equal to or greater than that of the positive control group. As another example, the neuroprotective effect may be measured by performing an in vivo animal experiment.

[0051] The peptide of the present invention has the exocrine gland secretion promoting effect of PACAP. Since the exocrine gland includes the lacrimal gland, the salivary gland, etc., it can be used as an exocrine gland secretion promoting agent, for example, a lacrimal secretion promoting agent or a salivary secretion promoting agent. Without intending to be limited by theory, PACAP and the peptide of the present invention promote the secretion of saliva and tears by binding to receptors (PAC1R, VPAC1R, VPAC2R) expressed in the acinar cells of the exocrine gland. Lacrimal fluid covers the surface of the cornea and conjunctiva, maintaining its wettability, and filling the depressions caused by the microvilli on the corneal surface to smooth the surface, making it possible to obtain a clear image. In addition, the epithelial cells of the cornea and conjunctiva actively metabolize, and unnecessary cells and metabolic products are excreted from the outermost surface, but lacrimal fluid washes them away while supplying necessary oxygen and nutrients. Furthermore, tears wash away foreign matter that has invaded the corneal and conjunctival surfaces, and play a role in preventing infections against viruses, bacteria, fungi, etc. that have invaded from the outside world through the bacteriostatic action of tears. In addition, as a synovial fluid between the eyelids and the corneal and conjunctival membranes, tears work to facilitate smooth blinking and eye movement. Thus, tears are a very small amount of liquid that forms a thin film on the corneal and conjunctival surfaces, but due to various sophisticated mechanisms, they are indispensable for maintaining the transparency and homeostasis of the cornea. A condition in which abnormalities occur on the corneal and conjunctival surfaces due to impaired tear secretion is generally called dry eye. When corneal and conjunctival disorders occur due to dry eye, the creation of a compound that promotes tear secretion can be a useful preventive and therapeutic drug for dry eye and diseases associated with dry eye. The peptide of the present invention can be incorporated into eye drops such as eye drops as a tear secretion promoter.

[0052] The peptide of the present invention can be used as an anti-inflammatory agent since it has the anti-inflammatory effect of PACAP. Without intending to be limited by theory, PACAP and the peptide of the present invention can suppress the production of inflammatory cytokines (TNF-α, IL-6, IL-12, etc.). Therefore, the peptide of the present invention can be used as an anti-inflammatory agent. In particular, VPAC1R and VPAC2R, which are receptors for PACAP, are widely distributed in the digestive tract and further exhibit anti-inflammatory effects, and therefore can be used in particular for the treatment of inflammatory bowel disease and the like.

[0053] In another aspect, the present invention also relates to a pharmaceutical composition comprising a therapeutically effective amount of the above peptide. The pharmaceutical composition of the present invention can be used for the treatment or prevention of a disease that is improved by the physiological action of PACAP. Examples of diseases that are improved by the physiological action of PACAP include neuropathy, diseases associated with decreased tear volume, inflammatory diseases, and neurotrophic keratitis. The pharmaceutical composition of the present invention can be administered to a patient to treat a disease that is improved by the physiological action of PACAP, or can be administered to a patient who may suffer from such a disease to prevent the disease. In addition, "treatment" refers to preventing the deterioration of a condition when a disorder or disease develops, and maintaining, alleviating, or eliminating the condition, and "prevention" refers to preventing the onset of a disorder or disease before it develops.

[0054] Neurological disorders are pathological conditions in which the function of nerve cells is impaired due to degeneration or cell death, and include cerebrovascular disorders and neurodegenerative diseases.

[0055] Cerebrovascular disorders include hemorrhagic disorders such as cerebral hemorrhage and subarachnoid hemorrhage, and disorders due to occlusion of cerebral blood vessels such as cerebral thrombosis, cerebral infarction, and cerebral circulatory insufficiency. In both hemorrhagic disorders and occlusion disorders, nerve cells in the brain are placed in a hypoxic state, resulting in cell death. Therefore, the peptide, neuroprotective agent, or pharmaceutical composition according to the present invention can be administered for the purpose of treatment or prevention of such cerebrovascular disorders.

[0056] Neurodegenerative diseases include, but are not limited to, brain and central neurodegenerative diseases such as dementia, Parkinson's disease, spinocerebellar degeneration, Creutzfeldt-Jakob disease, Alzheimer's disease, Huntington's chorea, multiple sclerosis, mad cow disease, and epilepsy, motor neurodegenerative diseases such as progressive spinal muscular atrophy, amyotrophic lateral sclerosis, and bulbospinal muscular atrophy, and sensory neurodegenerative diseases. Sensory neurodegenerative diseases include, but are not limited to, degenerative diseases of the visual, auditory, tactile, gustatory, and olfactory nerves. Visual degenerative diseases include glaucoma, retinitis pigmentosa, age-related macular degeneration, and diabetic retinopathy, and auditory neurodegenerative diseases include hearing loss.

[0057] Diseases associated with decreased tear volume include, but are not limited to, dry eye, keratoconjunctivitis sicca, and aqueous lacrimation.

[0058] Neurotrophic keratitis is a degenerative corneal disease caused by damage to the trigeminal nerve, leading to damage to the corneal epithelium. In its most severe form, it can lead to ulceration, melting, or perforation of the cornea, impairing the patient's ability to see.

[0059] Vascular endothelial function improvers refer to drugs that improve the function of vascular endothelium. Vascular endothelial cells are cells in the innermost layer of blood vessels, and they are responsible for contraction and relaxation of the vascular wall (hardness and softness of the blood vessel), adhesion of inflammatory cells to the vascular wall, vascular permeability, and regulation of the coagulation and fibrinolysis systems. The peptide of the present invention has a vasodilatory effect, which is the physiological effect of PACAP, and therefore has an effect of improving vascular endothelial disorders such as arteriosclerosis.

[0060] Corneal epithelial or endothelial disorder is a disease in which corneal epithelial cells and corneal endothelial cells are damaged. Corneal epithelial cells are proliferative cells, but in corneal epithelial cell damage, the balance of epithelial homeostasis is lost when the proliferation ability is suppressed or epithelial shedding is accelerated, resulting in the onset of corneal epithelial cell damage. Corneal endothelial cells do not proliferate in vivo, and decrease with age. In addition, corneal epithelial or endothelial disorder means that the corneal epithelium or endothelium is damaged by endogenous diseases such as corneal ulcer, corneal epithelial peeling, diabetic keratopathy, keratoconjunctivitis sicca, chronic superficial keratitis, punctate superficial keratopathy, corneal erosion, and persistent corneal epithelial defect, exogenous diseases due to drugs, trauma, contact lens wearing, etc., or physical or chemical disorders.

[0061] Dry eye is a chronic disease of the tears and corneal and conjunctival epithelium caused by various factors, which is accompanied by ocular discomfort and visual dysfunction. Abnormalities in tears include quantitative abnormalities in which the amount of tears is reduced, and qualitative abnormalities in which the properties of tears and the ability to retain tears are changed. Examples of dry eye include dry eye associated with aqueous hypolacrimia, hyperevaporative dry eye, Sjögren's syndrome, Stevens-Johnson syndrome, corneal epithelial erosion, marginal blepharitis, ocular pemphigoid, vernal conjunctivitis, allergic conjunctivitis, and vitamin A deficiency.

[0062] Inflammatory diseases include, but are not limited to, asthma, atopic dermatitis, urticaria, hay fever, anaphylactic shock, sinusitis (including eosinophilic sinusitis), rheumatism, multiple sclerosis, arthritis, systemic lupus erythematosus, psoriasis, ankylosing spondylitis, inflammatory bowel disease (e.g., ulcerative colitis, Crohn's disease, gluten-sensitive enteropathy, etc.), Sjogren's syndrome, chronic graft-versus-host disease (GVHD), corneal infection, allergic conjunctivitis, corneal trauma, polymyositis, dermatomyositis, myasthenia gravis, chronic obstructive pulmonary disease (COPD), and scleroderma.

[0063] The peptide according to the present invention, or a neuroprotective agent, a neuroregenerative agent, an inflammation suppressant, a wound healing promoter, or an exocrine gland secretion promoter, or a pharmaceutical composition containing the peptide, may be administered parenterally or orally depending on the disease to be treated. Oral administration includes sublingual, oral, and internal administration. Parenteral administration may be, for example, intravenous, intraarterial, subcutaneous, topical, intraperitoneal, intramuscular, nasal, transdermal, transmucosal, intrameningeal, rectal, intramuscular, intracerebral, intrameningeal, subarachnoid, intradural, epidural, eye drop, ear drop, nasal, or intraocular. More specifically, the intraocular route may be subconjunctival, sub-Tenon, or intravitreal. The pharmaceutical composition containing the peptide of the present invention can be appropriately formulated according to the administration route, and may be, for example, eye drops, injections, powders, infusion preparations, granules, tablets, suppositories, etc., but from the viewpoint of parenteral administration, eye drops, injections, infusion preparations, powders for preparation when used, etc. are preferred. Examples of preparations for intraocular administration include intravitreal injections, subconjunctival injections, and sub-Tenon's injections. These preparations may also contain various pharma- ceutical acceptable adjuvants, i.e., carriers and other auxiliary agents, such as stabilizers, preservatives, soothing agents, emulsifiers, and other additives. They may also be used in combination with other drugs having neuroprotective effects, anti-inflammatory effects, or exocrine gland secretion effects.

[0064] All documents mentioned herein are incorporated by reference in their entirety.

[0065] The following examples of the present invention are for illustrative purposes only and do not limit the technical scope of the present invention. The technical scope of the present invention is limited only by the claims. The present invention can be modified, for example, by adding, deleting, and replacing the constituent elements of the present invention, without departing from the spirit of the present invention. EXAMPLES

[0066] Example 1A: Synthesis of Fmoc-(D)-Tz(Trt)-OH (Compound IV) Fmoc-D-Tz(Trt)-OH (Compound IV) was synthesized according to the following reaction scheme. [ka]

[0067] Step A: Synthesis of Fmoc-D-Ala(β-CN)-OH: [ka]

[0068] A solution of Fmoc-D-Asn-OH (5.04 g, 14 mmol) in acetonitrile (35 mL) was added with a suspension of pyridine (30 mL) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (3.96 g, 21 mmol) in acetonitrile (35 mL) at 0°C, and the mixture was stirred at room temperature for 4 hours. The reaction solution was concentrated under reduced pressure, and ethyl acetate was added to the residue, which was washed with 3M hydrochloric acid and saturated saline, dried over sodium sulfate, and the solvent was removed by distillation under reduced pressure. The obtained crude product was dissolved in acetone, precipitated by adding hexane / diethyl ether (1 / 1), concentrated under reduced pressure, and filtered to obtain the target compound (4.76 g, 99%) as a white solid. 1 H NMR (400 MHz, DMSO-d6) δ 13.20 (1H, brs), 8.08 (1H, d, J = 8.4 Hz), 7.90 (2H, d, J = 7.6 Hz), 7.72 (2H, d, J = 7.2 Hz), 7.42 (2H, t, J = 7.2 Hz), 7.33 (2H, t, J = 7.6 Hz), 4.39-4.32 (3H, m), 4.25 (1H, t, J = 7.2 Hz), 2.98 (1H, dd, J = 16.8, 4.8 Hz), 2.88 (1H, dd, J = 16.8, 9.2 Hz).

[0069] Step B: Synthesis of Fmoc-D-Tz-OH: [ka] In the above structural formula, this means that an H is bonded to either N1 or N2 on the tetrazole.

[0070] Dibutyltin oxide (0.710 g, 2.9 mmol) and trimethylsilyl azide (1.8 mL, 14 mmol) were added to a solution of Fmoc-D-Ala(β-CN)-OH (1.01 g, 3.0 mmol) in toluene (18 mL), and the mixture was heated at 100°C for 1.5 hours using a microwave. The reaction solution was returned to room temperature and filtered. The resulting filtrate was washed with toluene and hexane, dissolved in ethanol / dichloromethane (3 / 2.25 mL), cooled to 4°C, and then 1M hydrochloric acid (5 mL) was added and stirred at room temperature for 2 hours and 15 minutes. The reaction solution was washed with 1M hydrochloric acid and saturated saline, the solvent was removed by distillation under reduced pressure, hexane was added, the mixture was suspended, and the mixture was filtered to obtain the target compound (1.03 g, 90%) as a pale yellow solid. 1 H NMR(400 MHz, DMSO-d6) δ 16.00 (1H, brs), 13.07 (1H, brs), 7.89 (2H, d, H = 7.6 Hz), 7.83 (1H, d, J = 8.4 Hz), 7.65 (2H, t, J = 8.0 Hz), 7.41 (2H, t, J = 7.6 Hz), 7.31 (2H, t, J = 7.6 Hz), 4.53-4.48 (1H,m), 4.27-4.18 (3H, m), 3.40 (1H, dd, J = 15.2, 6.0 Hz), 3.28 (1H, dd, J = 15.2, 8.8 Hz).

[0071] Step C: Synthesis of Fmoc-D-Tz(Trt)-OH: [ka] In the above structural formula, this means that the Trt group is attached to N1 or N2 on the tetrazole.

[0072] To a solution of Fmoc-D-Tz-OH (1.99 g, 5.3 mmol) in THF (10 mL), N-methylmorpholine (0.72 mL, 7.2 mmol) and trityl chloride (1.63 g, 5.9 mmol) were added and stirred at room temperature for 1.5 hours. The reaction solution was filtered, the filtrate was washed with THF, and the filtrate was combined and the solvent was removed by distillation under reduced pressure. The residue was purified by column chromatography (ODS, H2O / CH3CN=80 / 20→30 / 70→20 / 80), and the fraction containing the target compound was extracted with ethyl acetate, washed with saturated saline, dried over sodium sulfate, the solvent was removed by distillation under reduced pressure, and the product was dried in vacuum at 60°C to obtain the target compound (1.29 g, 40%) as a white solid. 1 H NMR (400 MHz, DMSO-d6) δ 13.03 (1H, brs), 7.91 (2H, d, J = 7.6 Hz), 7.79 (1H,d, J = 8.8 Hz), 7.67 (2H, brd, J = 6.8 Hz), 7.44-7.23 (13H, m), 7.01-6.99 (6H, m), 4.52-4.46 (1H, m), 4.28-4.15 (3H, m), 3.40 (1H, dd, J = 15.2, 5.2 Hz), 3.27 (1H, dd, J = 15.2, 9.2 Hz).

[0073] Example 1B: Synthesis of Fmoc-nvTz(Trt)-OH (Compound X) Fmoc-nvTz(Trt)-OH (Compound X) was synthesized according to the following reaction scheme. [ka]

[0074] Process D: Boc-N ε Synthesis of -trifluoroacetyl-L-lysine: [ka]

[0075] N ε1M aqueous sodium hydroxide solution (42mL, 42mmol) and Boc2O (30% THF solution, 49.8g, 68mmol) were added to a solution of 1,4-dioxane (70mL) of 10.0g trifluoroacetyl-L-lysine (10.0g, 41mmol) and stirred at room temperature for 1 day. N-methylpiperazine (3.5mL) was added to the reaction solution and stirred at room temperature for 2 hours, after which the reaction solution was adjusted to pH 2 by adding 1M hydrochloric acid, extracted with ethyl acetate, and washed with saturated saline. The organic layer was dried over sodium sulfate, and the solvent was removed by distillation under reduced pressure to obtain the title compound (15.9g, >100%) as a white solid. 1 H NMR (400 MHz, CDCl3) δ 6.69 (1H, brs), 5.12 (1H, d, J = 6.8 Hz), 4.30 (1H, brs), 3.38 (2H, q, J = 6.8 Hz), 1.94-1.86 (1H, m), 1.74-1.57 (3H, m), 1.52-1.41 (3H, m), 1.45 (9H, s).

[0076] Step E: Synthesis of (S)-2-[(tert-butoxycarbonyl)amino]-5-cyanopentanoic acid [ka]

[0077] Add Boc-N to the flask. e-Trifluoroacetyl-L-lysine (1.00g, 2.9mmol), sodium hydroxide (276.4mg, 6.9mmol) and water (15mL) were added, and further an aqueous solution (1.0mL) of nickel(II) sulfate hexahydrate (77.0mg, 0.29mmol), sodium peroxodisulfate (1.43g, 6.0mmol) and sodium hydroxide (529.5mg, 13mmol) were added, and the mixture was stirred at room temperature for 19.5 hours. The reaction solution was adjusted to pH 2 with 1M hydrochloric acid, extracted with ethyl acetate, and the obtained organic layer was washed with saturated saline, dried over sodium sulfate, and the solvent was removed by distillation under reduced pressure. The residue was purified by silica gel column chromatography (dichloromethane / methanol = 100 / 0 → 95 / 5) to obtain the title compound (661.5mg, 86%) as a white solid. 1 H NMR (400 Mz, DMSO-d6) δ 12.53 (1H, brs), 7.14 (1H, d, J = 8.4 Hz), 3.93-3.88 (1H, m), 2.53-2.48 (2H, m), 1.81-1.74 (1H, m), 1.69-1.56 (3H, m), 1.39 (9H, m)

[0078] Step G: Synthesis of (S)-2-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)-5-cyanopentanoic acid: [ka]

[0079] A solution of (S)-2-[(tert-butoxycarbonyl)amino]-5-cyanopentanoic acid (586.3 g, 2.4 mmol) in dichloromethane (2.5 mL) was cooled to 0°C, trifluoroacetic acid (2.5 mL) was added, and the mixture was stirred at room temperature for 1 hour. The solvent of the reaction solution was removed by distillation under reduced pressure. 1,4-dioxane (3.0 mL) was added to the resulting residue, and 10% aqueous potassium carbonate solution and solid potassium carbonate were added until the pH reached 9, followed by Fmoc-OSu (1.26 g, 3.7 mmol) and stirring at room temperature for 2 hours. The reaction solution was diluted with an ethyl acetate / hexane (1 / 1) solution, washed with 0.5 M hydrochloric acid and saturated saline, and the resulting organic layer was dried over sodium sulfate, and the solvent was removed by distillation under reduced pressure. The resulting residue was purified by silica gel column chromatography (ethyl acetate / hexane = 10 / 90 → 31 / 69) to obtain the title compound (731.1 mg, 83%) as a white solid. 1 H NMR (4000 MHz, CDCl3) δ 7.76 (2H, d, J = 7.2 Hz), 7.58 (2H, brd, J = 6.8 Hz), 7.40 (2H, t, J = 7.2 Hz), 7.31 (2H, t, J = 6.8 Hz), 5.38 (1H, d, J = 7.6 Hz), 4.64-4.36 (3H, m), 4.20 (1H, J = 6.4 Hz), 2.38 (1H, brt, J = 6.4 Hz), 2.28-2.07 (2H, m), 1.88-1.41 (3H, m)

[0080] Step H: Synthesis of Fmoc-nvTz-OH [ka] In the above structural formula, this means that H is bonded to either N1 or N2 on the tetrazole.

[0081] Trimethylsilyl azide (1.2 mL, 9.2 mmol) was added to a solution of (S)-2-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)-5-cyanopentanoic acid (851 mg, 2.3 mmol) and dibutyltin oxide (581 mg, 2.3 mmol) in toluene (17 mL), and the mixture was heated at 100° C. for 1.5 hours using a microwave. The reaction solution was returned to room temperature, filtered, and the obtained solid was washed with toluene and hexane to obtain a pale orange solid. Ethanol / dichloromethane (3 / 2.50 mL) was added to the solid, and the mixture was cooled to 0° C., after which 1M hydrochloric acid (5.0 mL) was added and the mixture was stirred at room temperature for 2 hours. Ethyl acetate was added to the reaction solution, which was washed with 1M hydrochloric acid and saturated saline, dried over sodium sulfate, and the solvent was removed by distillation under reduced pressure. The obtained residue was purified by silica gel column chromatography (dichloromethane / methanol=100 / 0→95 / 5) to obtain the title compound (367 mg, 39%). 1 H NMR (400 MHz, DMSO-d6) δ 7.88 (2H, d, J = 7.6 Hz), 7.72 (2H, d, J = 7.2 Hz), 7.63 (1H, d, J = 7.6 Hz), 7.40 (2H, t, J = 7.6 Hz), 7.31 (2H, t, J = 7.2 Hz), 4.29-4.20 (3H, m), 4.01-3.96 (1H, m), 2.89 (2H, m), 1.78-1.46 (5H, m).

[0082] Step I: Synthesis of Fmoc-nvTz(Trt)-OH [ka] In the above structural formula, this means that the Trt group is attached to either N1 or N2 on the tetrazole.

[0083] To a solution of Fmoc-nvTz-OH (365 mg, 0.89 mmol) in THF (4.0 mL), N-methylmorpholine (110 μL, 1.0 mmol) and trityl chloride (261 mg, 0.94 mmol) were added and stirred at room temperature for 2 hours. After completion of the reaction, the mixture was filtered, and the solvent of the obtained filtrate was removed by distillation under reduced pressure to obtain the title compound (540 mg, 93%) as a white solid. 1 H NMR (400 MHz, DMSO-d6) δ 12.67 (1H, s), 7.89 (2H, d, J = 7.2 Hz), 7.72 (2H, m), 7.66 (1H, brs), 7.39-7.19 (13H, m), 7.02-6.98 (6H, m), 4.34-4.20 (3H, m), 3.98-3.94 (1H, m), 2.88-2.83 (2H, m), 1.77-1.62 (4H, m)

[0084] Example 1C: Synthesis of (S)-2-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)-3-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)propanoic acid (Compound XV) According to the following reaction scheme, (S)-2-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)-3-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)propanoic acid (compound XV) was synthesized. [ka]

[0085] Step I: Synthesis of tert-butyl (S)-2-[(tert-butoxycarbonyl)amino]-3-cyanopropanoate [ka]

[0086] 2-Bromo-2-methylpropane (46 ml, 409 mmol) was added to a suspension of Boc-Ala(CN)-OH (2.23 g, 10.4 mmol), benzyltriethylammonium chloride (2.38 g, 10.4 mmol) and potassium carbonate (37.0 g, 268 mmol) in DMA (60 mL), and the mixture was stirred at 55° C. for 1 day. The reaction solution was returned to room temperature, water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated saline, dried over sodium sulfate, and the solvent was removed by distillation under reduced pressure. The residue was purified by flash silica gel column chromatography (hexane / ethyl acetate=1 / 0→1 / 4) to obtain the title compound (2.79 g, 99%) as a transparent oily substance. 1 H NMR (400 MHz, CDCl3) δ 5.45 (1H, brd, J = 4.8 Hz), 4.37 (1H, brq, J = 5.2 Hz), 2.94 (1H, dd, J = 16.8, 5.2 Hz), 2.88 (1H, dd, J = 16.8, 4.8 Hz), 1.51 (9H, s), 1.45 (9H, s).

[0087] Step J: Synthesis of tert-butyl (S)-2-[(tert-butoxycarbonyl)amino]-4-(hydroxyamino)-4-iminobutanoate [ka]

[0088] To a solution of tert-butyl (S)-2-[(tert-butoxycarbonyl)amino]-3-cyanopropanoate (2.79 g, 10 mmol) in ethanol (30 mL), triethylamine (2.8 mL, 20 mmol) and hydroxylamine hydrochloride (1.08 g, 16 mml) were added and stirred at 95° C. for 4 hours. The reaction solution was returned to room temperature, water was added, extracted with ethyl acetate, dried over sodium sulfate, the solvent was removed by distillation under reduced pressure, and dried in vacuum to obtain the title compound (2.85 g, 91%) as a white amorphous substance. 1H NMR (400 MHz, CDCl3) δ 6.47 (1H, brs), 5.47 (1H, brs), 4.63 (2H, brs), 4.37 (1H, brs), 2.62-2.54 (2H, m), 1.46 (9H, s), 1.44 (9H, s).

[0089] Step K: Synthesis of tert-butyl (S)-2-[(tert-butoxycarbonyl)amino]-3-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)propanoate [ka]

[0090] 1,1-carbonyldiimidazole (627 mg, 3.9 mmol) was added to a solution of tert-butyl (S)-2-[(tert-butoxycarbonyl)amino]-4-(hydroxyamino)-4-iminobutanoate (1.04 g, 3.4 mmol) in THF (20 mL), and the mixture was stirred at room temperature for 1.5 hours. The reaction solution was concentrated, toluene (20 mL) was added, and the mixture was stirred at 100° C. for 2 hours. The reaction solution was returned to room temperature, the solvent was removed by distillation under reduced pressure, and the resulting residue was purified by flash silica gel column chromatography (hexane / ethyl acetate=1 / 1) to obtain the title compound (658.9 mg, 58%) as a white amorphous substance. 1 H NMR (400 MHz, DMSO-d6) δ 12.23 (1H, brs), 7.36 (1H, d, J = 8.0 Hz), 4.24 (1H, q, J = 8.0 Hz), 2.90 (1H, dd, J = 15.2, 7.2 Hz), 2.81 (1H, dd, J = 15.2, 8.4 Hz), 1.38 (9H, s), 1.37 (9H, s).

[0091] Step L: Synthesis of (S)-2-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)-3-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)propanoic acid [ka]

[0092] To a solution of tert-butyl (S)-2-[(tert-butoxycarbonyl)amino]-3-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)propanoate (658.9 mg, 2.0 mmol) in dichloromethane (4.0 mL), triethylsilane (1.0 mL) and trifluoroacetic acid (5.0 mL) were added at 0° C., and the mixture was stirred at room temperature for 3 hours. The solvent was removed by distillation under reduced pressure, diethyl ether and hexane were added, and the solvent was removed again by distillation under reduced pressure, 1,4-dioxane (10 mL) was added, and a saturated aqueous solution of sodium bicarbonate was added until the pH reached 9. Then, Fmoc-OSu (813 mg, 2.4 mmol) was added at 0° C., and the mixture was stirred at room temperature overnight. The reaction solution was added with 10% aqueous citric acid solution to adjust the pH to 3, extracted with ethyl acetate, dried over sodium sulfate, and the solvent was removed by distillation under reduced pressure. The resulting residue was purified by silica gel column chromatography (dichloromethane / methanol = 100 / 0 → 93 / 7) to obtain the title compound (465.3 mg, 59%) as a white amorphous substance. 1 H NMR (400 MHz, DMSO-d6) δ 7.89 (2H, d, J = 7.2 Hz), 7.70-7.63 (3H, m), 7.42 (2H, t, J = 7.2 Hz), 7.32 (2H, t, J = 7.2 Hz), 4.33-4.20 (4H, m), 2.96 (1H, dd, J = 15.2, 5.6 Hz), 2.80 (1H, dd, 15.2, 8.8 Hz),

[0093] Example 2: Peptide synthesis The peptides used in the test were synthesized by solid-phase synthesis using the Fmoc method using a peptide synthesizer (model: PSSM-8, manufactured by Shimadzu Corporation). The unnatural amino acids Fmoc-Tz-OH, Fmoc-Tz(trt)-OH, and Fmoc-egTz(trt)-OH used in the solid-phase synthesis were purchased from Astatech, Fmoc-cya-OH was purchased from Anaspec, and the compounds (IV), (X), and (XV) synthesized in Example 1 were used. In addition, F-moc-Ai-OH and Fmoc-Cn-OH were purchased from Watanabe Chemical Industry, and peptides 1 to 28 having the following sequences were synthesized. The molecular weights of the synthetic peptides were determined by mass spectrometry (MALDI TOF). As shown in Table 2 below, all measured values ​​were in good agreement with the theoretical values. The N-terminus and C-terminus were modified by methods well known to those skilled in the art. [Table 2-1] [Table 2-2] [Table 2-3]

[0094] In the table, Tz stands for tetrazole-substituted aspartic acid, egTz stands for tetrazole-substituted glutamic acid, nvTz stands for tetrazole-substituted homoglutamic acid, cya stands for sulfoxy-substituted aspartic acid, (5Oxa) stands for oxadiazolone-substituted aspartic acid, Ai stands for α-aminoisobutyric acid, and Cn stands for β-cyanoalanine. Tz(D) indicates that the tetrazole-substituted aspartic acid is the D-form.

[0095] Tz introduced into peptides 1 to 9 is racemic. Amino acids used in other peptides are in the L-form unless otherwise specified.

[0096] Example 3: Stability Study 1 [Preparation of measurement sample 1] The peptides (peptides 1-9) synthesized in Example 2 were weighed and dissolved in 0.1% phosphate buffer (pH 7.0) to prepare a 1.0 mM peptide solution. The 1.0 mM peptide solution was further diluted to 100 μM with phosphate buffer. The solution was filtered through a chromatodisk (Merck Millex-GV, 0.22 μm, manufactured by Merck Millipore), and the filtrate was dispensed into an LC vial (Waters Deactivated Qsert Vial). The prepared peptide solution was incubated in a thermostatic bath at 40°C for one or two months to obtain a post-storage sample. In addition, a sample of the peptide solution prepared at the same time that was not subjected to storage was used as a standard sample (initial sample). The standard sample and the post-storage sample were stored at -30°C until sample analysis.

[0097] [Moisture permeability] The total weight of the peptide solution and the storage container was regarded as the sample weight, and the weight of the sample before storage was weighed, and the weight of the sample after storage under each condition was also weighed. In addition, the empty weight of the storage container was weighed, and the moisture permeability was calculated according to the following formula.

number

[0098] The standard sample and the preserved sample were stirred with a vortex mixer, and the peptide solution was transferred to an HPLC vial (Waters Deactivated Qsert vial). The peptide solution was analyzed by reverse phase HPLC (HPLC system: Shimadzu Prominence) under the conditions in Table 3 below, and a chromatogram was obtained.

[0099] [HPLC analysis conditions] Column: Waters XSelect CSH C18, 5 μm, 4.6×250 mm, Guard column: Waters XSelect CSH C18, 5 μm, 4.6×20 mm Guard Cartridge Detection wavelength: 220nm Mobile phase A: 0.1% formic acid in water, Mobile phase B: 0.1% formic acid in acetonitrile Measurement time: 30 minutes Measurement sample injection volume: 50 μL Flow rate 1.0mL / min Column temperature: 40℃ Delivery of mobile phase: The mixing ratio of mobile phase A and mobile phase B was changed as shown in Table 3 below to control the linear concentration gradient. [Table 3]

[0100] In the chromatogram, the peak area value of the peptide was obtained, and the residual rate (residual rate before moisture correction) was calculated using formula (2). In addition, the residual rate after moisture correction was calculated from the residual rate before moisture correction by taking into account the permeability of the container according to formula (3).

number

number

[0101] The residual rates of peptides in the samples after storage, corrected for moisture content, are shown in Table 4. [Table 4] All peptides showed higher aqueous stability at 40°C for 4 and 8 weeks compared to PACAP27.

[0102] [Preparation of measurement sample 2] The peptide solutions prepared in the same manner as in [Preparation of measurement sample 1] for the peptides (peptides 13-16) synthesized in Example 2 were incubated in a thermostatic chamber at 40°C for 2 and 8 weeks to obtain samples after storage. Among the peptide solutions prepared at the same time, samples that were not subjected to storage were used as standard samples (initial samples). The standard samples and the samples after storage were stored at -30°C until sample analysis.

[0103] [HPLC analysis conditions] Only the measurement time and the mobile phase delivery conditions were changed as follows, and the rest were the same as those in the [Measurement sample preparation 1] section: Measurement time: 20 minutes Delivery of mobile phase: The mixing ratio of mobile phase A and mobile phase B was changed as shown in Table 5 below to control the linear concentration gradient. [Table 5]

[0104] The residual rates of peptides in the samples after storage, corrected for moisture content, are shown in Table 6. [Table 6] Peptides with different tetrazole configurations and different lengths between the tetrazole and the peptide backbone also showed higher stability than PACAP27.

[0105] [Preparation of measurement sample 3] The peptide solutions prepared in the same manner as in [Preparation of measurement sample 1] for the peptides (peptides 17 to 21) synthesized in Example 2 were incubated in a thermostatic chamber at 40°C for 4 weeks to obtain post-storage samples. Among the peptide solutions prepared at the same time, a sample that was not subjected to storage was used as a standard sample (initial sample). The standard sample and post-storage sample were stored at -30°C until sample analysis.

[0106] [HPLC analysis conditions] Only the measurement time and the mobile phase delivery conditions were changed as follows, and the rest were the same as those in the [Measurement sample preparation 1] section: Measurement time: 20 minutes Delivery of mobile phase: The mixing ratio of mobile phase A and mobile phase B was changed as shown in Table 7 below to control the linear concentration gradient. [Table 7]

[0107] The residual rates of peptides in the samples after storage, corrected for moisture content, are shown in Table 8. [Table 8] Peptides with different acyl groups substituted at the N-terminus showed higher stability than PACAP27.

[0108] [Preparation of measurement sample 4] The peptide solution prepared for peptide 22 synthesized in Example 2 by the same method as in [Preparation of measurement sample 1] was incubated in a thermostatic chamber at 40°C for 1 week and 4 weeks to obtain a post-storage sample. In addition, among the peptide solutions prepared at the same time, a sample that was not subjected to storage was used as a standard sample (initial sample). The standard sample and the post-storage sample were stored at -30°C until sample analysis.

[0109] [HPLC analysis conditions] Only the measurement time and the mobile phase delivery conditions were changed as follows, and the rest were the same as those in the [Measurement sample preparation 1] section: Measurement time: 20 minutes Delivery of mobile phase: The mixing ratio of mobile phase A and mobile phase B was changed as shown in Table 9 below to control the linear concentration gradient. [Table 9]

[0110] The residual rates of peptides in the samples after storage, corrected for moisture content, are shown in Table 10. [Table 10] Peptides in which the tetrazole-substituted aspartic acid was replaced by an oxadiazolone-substituted aspartic acid at positions 3 and 8 showed higher stability than PACAP27.

[0111] [Preparation of measurement sample 5] Peptides 23 to 30 synthesized in Example 2 were weighed and dissolved in Tris buffer (pH 7.0) to prepare a 1.0 mM peptide solution. This solution was filtered through a chromatodisk (Merckmillipore Millex-GV, 0.22 μm). The filtrate was diluted to 100 μM with Tris buffer (pH 7.0) and dispensed into tubes (Eppendorf Protein Lobind Tubes). The prepared peptide solution was incubated in a 40°C incubator for 4 or 8 weeks, and in a 60°C incubator for 1 or 2 weeks to obtain a post-storage sample. Among the peptide solutions prepared at the same time, a sample that was not subjected to storage was used as a standard sample (initial sample). The standard sample was stored at -30°C, and the post-storage sample was stored at -30°C until sample analysis.

[0112] [HPLC analysis conditions 1] Only the measurement time and the mobile phase delivery conditions were changed as follows, and the rest were the same as those in the [Measurement sample preparation 1] section: Measurement time: 20 minutes Delivery of mobile phase: The mixing ratio of mobile phase A and mobile phase B was changed as shown in Table 11 below to control the linear concentration gradient. [Table 11]

[0113] For peptide 30 only, the following gradient times were used: [Table 12]

[0114] The moisture-corrected residual rates of peptides in the samples after storage are shown in Table 13. [Table 13]

[0115] Example 4: Stability Study 2 For a peptide selected from the group consisting of peptides 1 to 16, an N-terminally acylated peptide is prepared. For a peptide selected from the group consisting of peptides 17 to 30, an N-terminally unacylated peptide is prepared. For the N-terminally modified peptide and the N-terminally unmodified peptide, each is dissolved in Tris buffer (pH 7.0) to prepare a 1.0 mM peptide solution. This solution was filtered through a chromatodisk (Merckmillipore Millex-GV, 0.22 μm). The filtrate was diluted to 100 μM with Tris buffer (pH 7.0) and dispensed into tubes (Eppendorf Protein Lobind Tubes). The prepared peptide solution was incubated in a thermostatic bath at 60°C for one or two weeks to obtain a post-storage sample. In addition, a sample of the peptide solution prepared at the same time that was not subjected to storage was used as a standard sample (initial sample). The standard sample and the post-storage sample were stored at -30°C until sample analysis.

[0116] The post-storage sample is analyzed under appropriate HPLC analysis conditions, and the moisture-corrected residual rate of the peptide in the post-storage sample is calculated in the same manner as in Example 3. It can be confirmed that the stability is improved in peptides that have been N-terminally modified, particularly N-terminally acylated, and further acetylated.

[0117] Reference example: Stability test 3 The peptides prepared in Reference Examples 1 to 6 were weighed and dissolved in Tris buffer (pH 7.0) to prepare a 1.0 mM peptide solution. This solution was filtered through a chromatodisc (Merck Millex-GV, 0.22 μm, manufactured by Merck Millipore). The filtrate was diluted to 100 μM with Tris buffer (pH 7.0) and dispensed into tubes (Protein Lobind Tube, manufactured by Eppendorf). The prepared peptide solution was incubated in a thermostatic bath at 60° C. for one or two weeks to obtain a post-storage sample. In addition, a sample of the peptide solution prepared at the same time that was not subjected to storage was used as a standard sample (initial sample). The standard sample and the post-storage sample were stored at −30° C. until sample analysis.

[0118] The samples after storage were measured under the following HPLC analysis conditions, and the residual rates of peptides in the samples after storage, corrected for water content, were calculated in the same manner as in Example 3. The results are shown in Table 15.

[0119] [HPLC analysis conditions] Column: Waters XSelect CSH C18, 5 μm, 4.6×250 mm Guard column: Waters XSelect CSH C18, 5 μm, 4.6×20 mm Guard Cartridge Detection wavelength: 220nm Mobile phase A: 0.1% formic acid in water Mobile phase B: 0.1% formic acid in acetonitrile Measurement time: 20 minutes Measurement sample injection volume: 50 μL Flow rate 1.0mL / min Column temperature: 40℃ Sample cooler: 25℃ Delivery of mobile phase: The mixing ratio of mobile phase A and mobile phase B is changed as shown in Table 14 below to perform linear concentration gradient control. [Table 14]

[0120] The moisture-corrected residual rates of peptides in the samples after storage are shown in Table 15. [Table 15] Reference Example 1 (PACAP) was extremely poor in stability, 26.6% after 1 week storage at 60°C and 15.8% after 2 weeks storage, and Reference Example 2 in which the N-terminus of PACAP was acetylated also had the same stability. On the other hand, Reference Examples 3 and 4 in which the carboxyl groups of aspartic acid at positions 3 and 8 were substituted with tetrazole (in Reference Example 3, methionine at position 17 was further substituted with norleucine, and in Reference Example 4, methionine at position 17 was further substituted with leucine), showed significantly improved stability, 91.3% and 91.7% after 1 week storage at 60°C, and 82.4% and 84.8% after 2 weeks storage. Furthermore, Reference Examples 5 and 6 in which the N-terminus of Reference Examples 3 and 4 was acetylated showed further improved stability, 98.1% and 98.4% after 1 week storage at 60°C, and 92.9% and 92.8% after 2 weeks storage. Here, the accelerated tests of 1 week and 2 weeks at 60° C. correspond to about 1 year and about 2 years at room temperature (25° C.), respectively. Therefore, Reference Examples 5 and 6 are expected to be stable for 2 years (residual rate of 90% or more) at room temperature.

[0121] Example 5: cAMP assay of PACAP27 and its modified peptides [Cell culture] Mitomycin-treated frozen CHO-K1 cells (PAC1 or VPAC1 receptor highly expressing cell lines: purchased from DiscoveRx) were cultured at 1.35 × 10 4 After preparing the cells at 100 μl per well using Cell plating reagent (DiscoveRx), the cells were seeded onto a 96-well culture plate. The cells were cultured at 37°C in a 5% CO2 incubator for 18 to 24 hours to allow the cells to adhere to the plate.

[0122] [Reagent preparation] The powders of peptides 1 to 30 synthesized in Example 2 and Reference Example 1 (PACAP) were dissolved in water to 0.1 mM, and then diluted with Cell assay buffer (DiscoveRx) (containing 0.5 mM IBMX and 0.001% BSA) to 20 μM. A 5-fold dilution series was prepared from the solution using the same Cell assay buffer and used in the assay.

[0123] [cAMP assay] The cAMP assay was performed using Hit Hunter cAMP assay for Biologics kit (DiscoveRx, Cat. No. 90-0075LM25) according to the instructions attached to the kit. The cAMP antibody solution was mixed with the diluted solutions of peptides 1 to 30 at various concentrations to prepare a peptide-cAMP antibody mixture. Next, the medium was removed from the culture plate of CHO-K1 cells, washed with PBS, and the peptide-cAMP antibody mixture was added to the cells and incubated for 30 minutes at 37°C in a 5% CO2 atmosphere. Next, Working detection solution was added, and the culture plate was shaded with aluminum foil, and then incubated at 25°C for 1 hour. After incubation, Solution A was added, and the culture plate was shaded with aluminum foil, and then incubated at 25°C for 3 hours. Finally, the chemiluminescence signal was detected using a GloMax detector (Promega) under the conditions of Luminescence, Integration time (1 sec). The obtained relative luminescence unit (RLU) values ​​were analyzed using GraphPad Prism Ver 6.05 (Graph Pad, Inc.), and the EC 50 The value was calculated. [Table 16]

[0124] In summary, the peptides according to the present invention (peptides 1 to 30) have significantly improved stability in aqueous solutions compared to PACAP, and maintain the same physiological activity as PACAP. In particular, they have a shelf life of more than 2 years at room temperature, which allows them to be developed as liquid preparations, such as vials, ampoules, and eye drops.

[0125] Formulation examples A pharmaceutical agent containing the peptide of the present invention as an active ingredient can be produced, for example, by the following formulation. The pharmaceutical agent of the present invention will be explained in more detail with reference to formulation examples, but the present invention is not limited to these formulation examples.

[0126] 1. Capsules (1) Peptide 5 40mg (2) Lactose 70 mg (3) Microcrystalline cellulose 9 mg (4) Magnesium stearate 1 mg 1 capsule: 120mg Mix all of (1), (2), and (3) with half of (4) and granulate. Add the remaining (4) and encapsulate the whole in a gelatin capsule.

[0127] 2. Tablets (1) Peptide 6 40mg (2) Lactose 58mg (3) Cornstarch 18mg (4) Microcrystalline cellulose 3.5 mg (5) Magnesium stearate 0.5 mg 1 tablet 120mg Mix all of (1), (2), and (3), 2 / 3 of (4), and 1 / 2 of (5), then granulate. Add the remaining (4) and (5) to the granules, and press into tablets.

[0128] 3. Intravitreal injections in 1ml (1) Peptide 5 40mg (2) Refined white sugar 50mg (3) Sodium chloride 2.34 mg (4) Polysorbate 80, appropriate amount (5) Disodium hydrogen phosphate, appropriate amount (6) Sodium dihydrogen phosphate, appropriate amount (7) Appropriate amount of sterile purified water (1) to (6) are dissolved in (7) sterile purified water to prepare intravitreal injection solution.

[0129] 4. Eye drops in 100mL (1) Peptide 6 100mg (2) Trometamol 300mg (3) Sodium chloride 900 mg (4) Benzalkonium chloride, appropriate amount (5) Appropriate amount of sterile purified water (1) to (4) are dissolved in (5) sterile purified water, and the pH is adjusted to prepare an eye drop solution.

Claims

[Claim 1] HX 1 -DGX 2 -FX 3 -DX 4 -YX 5 -RYRKX 6 -X 7 -AVKKYLAAVL (SEQ ID NO: 3) {During the ceremony, X 1 is a neutral amino acid, X 2 is a neutral amino acid, X 3 is a neutral amino acid, X 4 is alanine, serine, Ai or Cn, X 5 is alanine, serine, Ai or Cn, X 6 is glutamine or alanine X 7 is a non-polar amino acid. a peptide having a sequence in which aspartic acid at positions 3 and 8 of the sequence represented by the formula (I) is independently substituted with a residue selected from the group consisting of tetrazole-substituted aspartic acid (Tz), tetrazole-substituted glutamic acid (egTz), tetrazole-substituted homoglutamic acid (nvTz), sulfoxy-substituted aspartic acid (cya), and oxadiazolone-substituted aspartic acid (5Oxa), or a modified sequence thereof, wherein the peptide has binding ability to PAC1R and VPAC1R, and the modified sequence is a sequence in which one or more amino acids have been deleted or added in the sequence of SEQ ID NO:3.

Citation Information

Patent Citations

  • Ophthalmic agent containing pacap peptide

    JP2009269818A

  • Peptide exhibiting neuroprotective action, and pharmaceutical containing the same

    JP2012232952A

  • Neuroprotective peptides

    JP2014510101A

  • Corneal neuritogenesis promoter containing pacap and its derivative

    WO2005102375A1